Cargando…

Continuous Activity Assay for HDAC11 Enabling Reevaluation of HDAC Inhibitors

[Image: see text] Histone deacetylase 11 (HDAC11) preferentially removes fatty acid residues from lysine side chains in a peptide or protein environment. Here, we report the development and validation of a continuous fluorescence-based activity assay using an internally quenched TNFα-derived peptide...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kutil, Zsófia, Mikešová, Jana, Zessin, Matthes, Meleshin, Marat, Nováková, Zora, Alquicer, Glenda, Kozikowski, Alan, Sippl, Wolfgang, Bařinka, Cyril, Schutkowski, Mike
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Chemical Society 2019
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6882135/ https://www.ncbi.nlm.nih.gov/pubmed/31788622 http://dx.doi.org/10.1021/acsomega.9b02808

Ejemplares similares

Comprehensive Mechanistic View of the Hydrolysis of Oxadiazole-Based Inhibitors by Histone Deacetylase 6 (HDAC6)
por: Motlová, Lucia, et al.
Publicado: (2023)

Continuous Fluorescent Sirtuin Activity Assay Based on Fatty Acylated Lysines
por: Zessin, Matthes, et al.
Publicado: (2023)

Application of Ligand- and Structure-Based Prediction Models for the Design of Alkylhydrazide-Based HDAC3 Inhibitors as Novel Anti-Cancer Compounds
por: Bülbül, Emre F., et al.
Publicado: (2023)

Docking, Binding Free Energy Calculations and In Vitro Characterization of Pyrazine Linked 2-Aminobenzamides as Novel Class I Histone Deacetylase (HDAC) Inhibitors
por: Bülbül, Emre F., et al.
Publicado: (2022)

Synthesis, Molecular Docking and Biological Characterization of Pyrazine Linked 2-Aminobenzamides as New Class I Selective Histone Deacetylase (HDAC) Inhibitors with Anti-Leukemic Activity
por: Ibrahim, Hany S., et al.
Publicado: (2021)

Human histone deacetylase 6 shows strong preference for tubulin dimers over assembled microtubules
por: Skultetyova, Lubica, et al.
Publicado: (2017)

Selectivity of Hydroxamate- and Difluoromethyloxadiazole-Based Inhibitors of Histone Deacetylase 6 In Vitro and in Cells
por: Ptacek, Jakub, et al.
Publicado: (2023)

Heterologous expression and purification of recombinant human protoporphyrinogen oxidase IX: A comparative study
por: Novakova, Zora, et al.
Publicado: (2021)

Generation and characterization of human U-2 OS cell lines with the CRISPR/Cas9-edited protoporphyrinogen oxidase IX gene
por: Novakova, Zora, et al.
Publicado: (2022)

Histone Deacetylase (HDAC) Inhibitors for the Treatment of Schistosomiasis
por: Ghazy, Ehab, et al.
Publicado: (2022)

Expression of Histone Deacetylases HDAC1, HDAC2, HDAC3, and HDAC6 in Invasive Ductal Carcinomas of the Breast
por: Seo, Jinwon, et al.
Publicado: (2014)

Clinicopathological features and prediction values of HDAC1, HDAC2, HDAC3, and HDAC11 in classical Hodgkin lymphoma
por: Huang, Renhong, et al.
Publicado: (2018)

Characterization of glutamate carboxypeptidase 2 orthologs in trematodes
por: Jedlickova, Lucie, et al.
Publicado: (2022)

Carbamates as Potential Prodrugs and a New Warhead for HDAC Inhibition
por: King, Kristina, et al.
Publicado: (2018)

Involvement of HDAC1 and HDAC3 in the Pathology of Polyglutamine Disorders: Therapeutic Implications for Selective HDAC1/HDAC3 Inhibitors
por: Thomas, Elizabeth A.
Publicado: (2014)

HDAC and HDAC Inhibitor: From Cancer to Cardiovascular Diseases
por: Yoon, Somy, et al.
Publicado: (2016)

Molecular Mechanism of Sirtuin 1 Modulation by the AROS Protein
por: Weiss, Sandra, et al.
Publicado: (2022)

Crystal structures of the mitochondrial deacylase Sirtuin 4 reveal isoform-specific acyl recognition and regulation features
por: Pannek, Martin, et al.
Publicado: (2017)

HDAC3 and HDAC8 are required for cilia assembly and elongation
por: Park, Seon-ah, et al.
Publicado: (2019)

Metabolism, HDACs, and HDAC Inhibitors: A Systems Biology Perspective
por: King, Jacob, et al.
Publicado: (2021)

A continuous sirtuin activity assay without any coupling to enzymatic or chemical reactions
por: Schuster, Sabine, et al.
Publicado: (2016)

Hydroxamic acid derivatives as HDAC1, HDAC6 and HDAC8 inhibitors with antiproliferative activity in cancer cell lines
por: Sixto-López, Yudibeth, et al.
Publicado: (2020)

The potential for histone deacetylase (HDAC) inhibitors as cestocidal drugs
por: Vaca, Hugo Rolando, et al.
Publicado: (2021)

Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer - overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression
por: Müller, Berit Maria, et al.
Publicado: (2013)

Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells
por: Knox, Tessa, et al.
Publicado: (2019)

The HDAC interaction network
por: Livyatan, Ilana, et al.
Publicado: (2013)

Divergent roles of HDAC1 and HDAC2 in the regulation of epidermal development and tumorigenesis
por: Winter, Mircea, et al.
Publicado: (2013)

Both HDAC5 and HDAC6 are required for the proliferation and metastasis of melanoma cells
por: Liu, Jiaqi, et al.
Publicado: (2016)

Development of First-in-Class Dual Sirt2/HDAC6 Inhibitors as Molecular Tools for Dual Inhibition of Tubulin Deacetylation
por: Sinatra, Laura, et al.
Publicado: (2023)

Author Correction: Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells
por: Knox, Tessa, et al.
Publicado: (2019)

Specific Control of Pancreatic Endocrine β- and δ-Cell Mass by Class IIa Histone Deacetylases HDAC4, HDAC5, and HDAC9
por: Lenoir, Olivia, et al.
Publicado: (2011)

Comprehensive Analysis of HDAC Family Identifies HDAC1 as a Prognostic and Immune Infiltration Indicator and HDAC1-Related Signature for Prognosis in Glioma
por: Fan, Yuxiang, et al.
Publicado: (2021)

Structure‐Based Design, Synthesis, and Biological Evaluation of Triazole‐Based smHDAC8 Inhibitors
por: Kalinin, Dmitrii V., et al.
Publicado: (2020)

Regulating the Regulators: The Post-Translational Code of Class I HDAC1 and HDAC2
por: Segré, Chiara V., et al.
Publicado: (2011)

HDAC1 and HDAC6 are essential for driving growth in IDH1 mutant glioma
por: Garrett, Matthew C., et al.
Publicado: (2023)

The Role of HDAC6 in Cancer
por: Aldana-Masangkay, Grace I., et al.
Publicado: (2011)

HDAC6 and Ovarian Cancer
por: Haakenson, Joshua, et al.
Publicado: (2013)

Class IIa HDACs in myelination
por: Velasco-Aviles, Sergio, et al.
Publicado: (2018)

HDAC1 and HDAC2 Regulate Oligodendrocyte Differentiation By Disrupting β-Catenin-TCF Interaction
por: Ye, Feng, et al.
Publicado: (2009)

HDAC6 as a target for neurodegenerative diseases: what makes it different from the other HDACs?
por: Simões-Pires, Claudia, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_fe3b42opqjnsf64n5r5ukt0tu0